Sagimet Biosciences Inc.
January 22, 2024 at 12:15 pm - by Joey Ramson
Shares of $SGMT are up after positive results from its phase 2b trial in metabolic-associated steatohepatitis, although there seems to have been a 20% dropout rate during the trial.
